The illusion of comfort that has defined much of American life in recent years is colliding with a far harsher reality taking shape beneath the surface. Robert Friedland, the influential billionaire investor and mining magnate, has been sounding the alarm that many…
Family offices are not just another line on the capital-raising target list; they are slow-moving, high-conviction decision engines run by people whose last name is on both the door and the check. Approaching them like just another fund is why most pitches…
Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…
India’s gold-backed lending boom is turning family heirlooms into the country’s most hardworking asset class, as households and small businesses increasingly march into bank branches with bangles instead of balance sheets. Rising gold prices, looser lending rules, and a vast, underutilized stockpile…
For decades, markets rewarded management teams that could master a strategy, stick to it, and talk about it in perfect bullet points. Today, investors are quietly rerating a different skill: the ability to discard that strategy on demand when the world—and the…
Hims & Hers (HIMS) just turned a courtroom drama into a growth story and its stock has flown +40% higher today, and a little-known insulin pump maker may be quietly scripting the sequel in metabolic health.
Hims & Hers: From GLP-1 Outlaw…
The U.S. Food and Drug Administration (FDA) is reportedly rolling out a new cash‑bonus program to reward drug reviewers who deliver high‑quality decisions ahead of schedule, a move pitched as both a modernization of government HR and a lifeline for an agency…
Oracle’s (ORCL) latest round of layoffs is less a retreat than a high‑stakes reshuffling for the age of artificial intelligence, as the software giant trades payroll for power plants in a bid to secure its place in the cloud big leagues.
A…
In the end, it was not a jury but a checkbook that settled one of biotech’s more closely watched intellectual-property dramas. Moderna will pay up to 2.25 billion dollars to Genevant Sciences and Arbutus Biopharma to resolve a global web of patent…
AST SpaceMobile (ASTS) is turning its long‑promised “cell tower in space” vision into a real, revenue‑generating business, and investors are finally getting numbers big enough to circle on a calendar instead of sketch on a napkin.
AST SpaceMobile’s First Big Leap:…
